Amylyx Pharmaceuticals (AMLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $34.00 price target on the stock.
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals (AMLX) had its price target raised by Guggenheim from $25.00 to $30.00. They now have a "buy" rating on the stock.
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. [Yahoo! Finance]